Shire Buys Dyax for up to $6.5 Billion
November 02, 2015.
Shire (Dublin, Ireland) and Dyax Corp. (Burlington, MA) today announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of approximately $5.9 billion. The acquisition furthers Shire’s strategy to become a leading global biotech. Dyax is a biotechnology company primarily focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease. Its most advanced clinical program is DX-2930, which has received fast track, breakthrough therapy, and orphan drug designations from FDA and has also received orphan drug status in the EU. It is expected to enter Phase 3 clinical trials by year-end 2015. If approved for the prevention of Type 1 and Type 2 HAE, DX-2930 could reportedly generate estimated annual global sales of up to $2.0 billion.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
